Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karyopharm Therapeutics Inc.
Report date February 28, 2019 · Filed March 04, 2019
Jointly reported with Chione Ltd, Czernik Marcin, Hadjimichael Andreas, Smolokowski Wiaczeslaw
Section 16 reporting ended · disclosed 2019-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 6,000,000 |
Reported balance
After 2019-02-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-02-28 · Sale · Disposed 149,624 · Balance 6,000,000 F1: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.04 to $4.25, inclusive. F2: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.04 to $4.25, inclusive.
F2: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above.
F3: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione.
F4: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed.
F5: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 4, 2019 20:28 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 149,624 | $4.14 | $619,114.19 |
DisclosureSEC source: 0001213900-19-003551 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold at prices ranging from $4.04 to $4.25, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| February 27, 2019 Filed Feb 27, 2019 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 558,243 | $4.51 | $2,515,833.73 |
DisclosureSEC source: 0001213900-19-003242 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,149,624 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 02/25/2019 at prices ranging from $4.80 to $5.31, inclusive, on 02/26/2019 at prices ranging from $5.00 to $5.08, inclusive, and on 02/27/2019 at prices ranging from $4.40 to $4.675, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 123,400 | $5.00 | $617,209.78 |
DisclosureSEC source: 0001213900-19-003242 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,707,867 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 02/25/2019 at prices ranging from $4.80 to $5.31, inclusive, on 02/26/2019 at prices ranging from $5.00 to $5.08, inclusive, and on 02/27/2019 at prices ranging from $4.40 to $4.675, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 800,000 | $4.99 | $3,994,880.00 |
DisclosureSEC source: 0001213900-19-003242 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,831,267 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 02/25/2019 at prices ranging from $4.80 to $5.31, inclusive, on 02/26/2019 at prices ranging from $5.00 to $5.08, inclusive, and on 02/27/2019 at prices ranging from $4.40 to $4.675, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| September 06, 2018 Filed Sep 7, 2018 18:27 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 4,800 | $20.52 | $98,473.92 |
DisclosureSEC source: 0001213900-18-012296 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,631,267 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 09/05/2018 at prices ranging from $21.00 to $21.50, inclusive, and on 09/06/2018 at prices ranging from $20.50 to $20.605, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 18:27 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 160,000 | $21.06 | $3,370,256.00 |
DisclosureSEC source: 0001213900-18-012296 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,636,067 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 09/05/2018 at prices ranging from $21.00 to $21.50, inclusive, and on 09/06/2018 at prices ranging from $20.50 to $20.605, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| September 04, 2018 Filed Sep 4, 2018 18:59 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 40,000 | $20.60 | $824,072.00 |
DisclosureSEC source: 0001213900-18-012091 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,796,067 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 08/30/2018 at prices ranging from $20.31 to $21.61, inclusive, on 08/31/2018 at prices ranging from $21.00 to $21.22, inclusive, and on 09/04/2018 at prices ranging from $20.50 to $20.82, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 18:59 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 11,468 | $21.05 | $241,395.67 |
DisclosureSEC source: 0001213900-18-012091 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,836,067 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 08/30/2018 at prices ranging from $20.31 to $21.61, inclusive, on 08/31/2018 at prices ranging from $21.00 to $21.22, inclusive, and on 09/04/2018 at prices ranging from $20.50 to $20.82, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 18:59 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 200,000 | $21.00 | $4,199,900.00 |
DisclosureSEC source: 0001213900-18-012091 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,847,535 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 08/30/2018 at prices ranging from $20.31 to $21.61, inclusive, on 08/31/2018 at prices ranging from $21.00 to $21.22, inclusive, and on 09/04/2018 at prices ranging from $20.50 to $20.82, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 29, 2018 Filed Aug 29, 2018 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 200,000 | $19.59 | $3,918,280.00 |
DisclosureSEC source: 0001213900-18-011892 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,047,535 F1 · shares: The prices reported in Column 4 are weighted average prices. The shares were sold on 08/27/2018 at prices ranging from $18.50 to $18.65, inclusive, and on 08/29/2018 at prices ranging from $19.00 to $20.01, inclusive. F2 · shares: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 14,026 | $18.52 | $259,775.55 |
DisclosureSEC source: 0001213900-18-011892 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,247,535 F1 · shares: The prices reported in Column 4 are weighted average prices. The shares were sold on 08/27/2018 at prices ranging from $18.50 to $18.65, inclusive, and on 08/29/2018 at prices ranging from $19.00 to $20.01, inclusive. F2 · shares: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 10, 2018 Filed Aug 14, 2018 19:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 702 | $18.50 | $12,987.00 |
DisclosureSEC source: 0001213900-18-011094 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,261,561 F1 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F2 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F3 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 09, 2018 Filed Aug 9, 2018 20:24 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 67,474 | $18.51 | $1,248,781.80 |
DisclosureSEC source: 0001213900-18-010635 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,262,263 F1 · price: The prices reported in Column 4 for the sales on 08/08/2018 and 08/09/2018 are weighted average prices. The shares were sold on 08/08/2018 at prices ranging from $18.6 to $18.625, inclusive, and on 08/09/2018 at prices ranging from $18.5 to $18.705, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 20:24 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 2,800 | $18.61 | $52,098.48 |
DisclosureSEC source: 0001213900-18-010635 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,329,737 F1 · price: The prices reported in Column 4 for the sales on 08/08/2018 and 08/09/2018 are weighted average prices. The shares were sold on 08/08/2018 at prices ranging from $18.6 to $18.625, inclusive, and on 08/09/2018 at prices ranging from $18.5 to $18.705, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:24 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 10,602 | $18.60 | $197,197.20 |
DisclosureSEC source: 0001213900-18-010635 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,332,537 F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 25, 2018 Filed Jul 25, 2018 19:55 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 895 | $18.52 | $16,571.01 |
DisclosureSEC source: 0001213900-18-009659 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,343,139 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 07/23/2018 at prices ranging from $18.47 to $18.91, inclusive, on 07/24/2018 at prices ranging from $18.6 to $18.72, inclusive, and on 07/25/2018 at prices ranging from $18.5 to $18.59, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 24, 2018 Filed Jul 25, 2018 19:55 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 9,144 | $18.63 | $170,341.75 |
DisclosureSEC source: 0001213900-18-009659 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,344,034 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 07/23/2018 at prices ranging from $18.47 to $18.91, inclusive, on 07/24/2018 at prices ranging from $18.6 to $18.72, inclusive, and on 07/25/2018 at prices ranging from $18.5 to $18.59, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 19:55 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 20,000 | $18.66 | $373,222.00 |
DisclosureSEC source: 0001213900-18-009659 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,353,178 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 07/23/2018 at prices ranging from $18.47 to $18.91, inclusive, on 07/24/2018 at prices ranging from $18.6 to $18.72, inclusive, and on 07/25/2018 at prices ranging from $18.5 to $18.59, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 17:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 26,742 | $19.21 | $513,804.74 |
DisclosureSEC source: 0001213900-18-009536 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,373,178 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 07/19/2018 at prices ranging from $18.6 to $19.305, inclusive, and on 07/20/2018 at prices ranging from $19.2 to $19.28, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 19, 2018 Filed Jul 23, 2018 17:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 100,000 | $18.90 | $1,889,940.00 |
DisclosureSEC source: 0001213900-18-009536 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,399,920 F1 · price: The prices reported in Column 4 are weighted average prices. The shares were sold on 07/19/2018 at prices ranging from $18.6 to $19.305, inclusive, and on 07/20/2018 at prices ranging from $19.2 to $19.28, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 18, 2018 Filed Jul 18, 2018 19:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 30,000 | $18.53 | $556,005.00 |
DisclosureSEC source: 0001213900-18-009395 · ownership.xml · nonDerivative · entry 3 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,499,920 F1 · price: The prices reported in Column 4 for the sales on 07/16/2018 and 07/18/2018 are weighted average prices. The shares were sold on 07/16/2018 at prices ranging from $18.5 to $18.57, inclusive, and on 07/18/2018 at prices ranging from $18.5 to $18.615, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 17, 2018 Filed Jul 18, 2018 19:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 17,346 | $18.50 | $320,901.00 |
DisclosureSEC source: 0001213900-18-009395 · ownership.xml · nonDerivative · entry 2 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,529,920 F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 19:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCOMMON STOCK | 2,654 | $18.52 | $49,160.84 |
DisclosureSEC source: 0001213900-18-009395 · ownership.xml · nonDerivative · entry 1 Chione Ltd · CIK 0001590232 · 10% owner Czernik Marcin · CIK 0001591275 · 10% owner Hadjimichael Andreas · CIK 0001591256 · 10% owner Hadjimichael George · CIK 0001674499 · 10% owner Smolokowski Wiaczeslaw · CIK 0001591274 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,547,266 F1 · price: The prices reported in Column 4 for the sales on 07/16/2018 and 07/18/2018 are weighted average prices. The shares were sold on 07/16/2018 at prices ranging from $18.5 to $18.57, inclusive, and on 07/18/2018 at prices ranging from $18.5 to $18.615, inclusive. F2 · price: The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above. F3 · balance_after: Shares of Common Stock are owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and George Hadjimichael, may be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. Wiaczeslaw Smolokowski, the sole shareholder of Chione, may also be deemed to share voting and investment power and beneficial ownership of the shares of Common Stock directly owned by Chione. F4 · balance_after: Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person or any other person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Beneficial ownership of the securities covered by this statement is disclaimed. F5 · balance_after: Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person or any other person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.